| Metric | Q4 FY26 | Q3 FY26 | Q4 FY25 |
|---|---|---|---|
| Revenue from operations | 33.6 | 25.7 | 38.2 |
| Other income | 0.5 | 0.5 | 0.5 |
| Total income | 34.1 | 26.2 | 38.7 |
| Profit before exceptional items & tax | -1.3 | 0.8 | 0.4 |
| Exceptional items | 1.0 | 0.1 | 0.1 |
| Profit before tax | -2.3 | 0.7 | 0.4 |
| Net profit | -2.0 | 0.6 | 0.5 |
| Operating margin | -6.7% | 2.7% | 1.0% |
A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.
| Revenue, year on year | -12.00% |
|---|
BSE results filing, NSE: TTFL. Figures extracted from the filing.
Trident Texofab Ltd: key numbers
- Share price
- ₹21.50
- Market cap
- ₹32.24 Cr
- Revenue (annual)
- ₹118.0 Cr
- Net profit (annual)
- ₹0.70 Cr
- P/E (TTM)
- 153.2×Sector 55.7×
- Promoter holding
- 32.16%+0.00% QoQ
- FII holding
- 0.00%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Trident Texofab Ltd
All →Trident Texofab Promoter Buying: ₹0.01 Cr
Promoter group trust Hardik Desai Family Trust bought 5,412 Trident Texofab shares on BSE. Promoter stake rose from 6.95% to 6.99%.
- Value
- ₹0.01 Cr
- Promoter stake change
- +0.04%
Trident Texofab Promoter Buying
Hardik Desai Family Trust, a Promoter Group entity, bought 5,412 shares of Trident Texofab in the open market. Post-transaction holding rose to 6.99% of total equity.
- Promoter stake change
- +0.04%
Trident Texofab Annual General Meeting
Trident Texofab Limited has issued the notice for its 18th Annual General Meeting, scheduled for September 30, 2026, alongside its Annual Report for FY 2025-26.
Trident Texofab Other Announcement
Trident Texofab Limited has appointed M/s. PAAA & Associates as the Cost Auditor for the company, effective September 7, 2026.
Trident Texofab Board Meeting Outcome
Trident Texofab's board approved the Board's Report, called the 18th AGM for September 30, 2026, and appointed a cost auditor and scrutinizer.
Trident Texofab Credit Rating
CRISIL Ratings has withdrawn the credit rating for Trident Texofab Ltd. This action follows a recent review of the company's financial and operational standing.